NanoString Tec…
ProfileJobs

NanoString Technologies

Suggest Edit
    • Healthclinical researchgeneticshealthtechlife sciencesmedical diagnostics

    NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The Company's nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision. NanoString's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The nCounter-based Prosigna Breast Cancer Prognostic Gene Signature Assay is the first in vitro diagnostic assay to be marketed through the company's diagnostics business. The system is positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues.

    Revenue(FY, 2017)
    $114.9 M
    Market capitalization(2018-05-15)
    $284 M
    Type
    Public
    HQ
    Seattle, US
    Founded
    2003
    Size (employees)
    407 (est)
    Website
    nanostring.com
    NanoString Technologies was founded in 2003 and is headquartered in Seattle, US
    Report incorrect company information

    Key People/Management at NanoString Technologies

    Brad Gray

    Brad Gray

    President and Chief Executive Officer
    James Johnson

    James Johnson

    CFO
    William Young

    William Young

    Executive Chairman of the Board
    Wayne Burns

    Wayne Burns

    Senior Vice President, Operations & Administration

    NanoString Technologies Office Locations

    NanoString Technologies has offices in Seattle and Hong Kong
    Seattle, US (HQ)
    2000 530 Fairview Ave N
    Show all (2)
    Report incorrect company information

    NanoString Technologies Financials and Metrics

    NanoString Technologies Financials

    NanoString Technologies's revenue was reported to be $114.91 m in FY, 2017
    USD

    Revenue (Q1, 2018)

    		23.1 m

    Net income (Q1, 2018)

    		(19.2 m)

    EBIT (Q1, 2018)

    		(17.9 m)

    Market capitalization (15-May-2018)

    		284 m

    Closing share price (15-May-2018)

    		11

    Cash (31-Mar-2018)

    		15.6 m
    NanoString Technologies's current market capitalization is $284 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		31.4 m47.6 m62.7 m86.5 m114.9 m

    Revenue growth, %

    		52%32%38%

    Cost of goods sold

    		15 m

    Gross profit

    		16.4 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Revenue

    		8.4 m8.8 m10.9 m12.3 m11.6 m13.1 m15.7 m14.7 m22.6 m23.9 m18.1 m34.6 m23.1 m

    Cost of goods sold

    		3.8 m4.3 m

    Gross profit

    		4.6 m4.4 m

    Gross profit Margin, %

    		55%51%
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		9.9 m17.2 m21.9 m20.6 m26.1 m

    Accounts Receivable

    		8.3 m12.4 m19.7 m22.2 m19.6 m

    Inventories

    		6.8 m5.4 m3.9 m13.8 m20.1 m

    Current Assets

    		60.7 m95.3 m82.8 m113.8 m121.9 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Cash

    		19.3 m29 m21.2 m18.8 m14.3 m15.7 m16.6 m29.6 m19.3 m10.5 m5.4 m40.6 m15.6 m

    Accounts Receivable

    		6.8 m7.4 m9.1 m15.3 m10.5 m13.2 m12.9 m15.5 m25.2 m21 m16.7 m18.5 m16.3 m

    Inventories

    		5.7 m7.5 m6.4 m5.8 m7.9 m9.4 m11.7 m11.8 m12.5 m11.7 m14.5 m15.8 m19.1 m

    Current Assets

    		67.5 m104.3 m99.1 m92.9 m79.3 m81.5 m74.6 m87.2 m98.5 m90.7 m92.4 m138.9 m101.7 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(29.3 m)(50 m)(45.6 m)(47.1 m)(43.6 m)

    Depreciation and Amortization

    		1.8 m1.5 m2.4 m3 m3.4 m

    Inventories

    		(1.4 m)(1.3 m)(5.4 m)(5 m)(8.7 m)

    Accounts Payable

    		1.6 m21 k(166 k)869 k(110 k)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

    Net Income

    		(7.7 m)(11.4 m)(14.1 m)(12.1 m)(14.9 m)(12.4 m)(9.5 m)(14.6 m)(10.8 m)(10.1 m)(18.9 m)(19.2 m)

    Depreciation and Amortization

    		928 k

    Inventories

    		6.4 m5.8 m7.9 m9.4 m11.7 m11.8 m12.5 m11.7 m14.5 m817 k

    Accounts Payable

    		2.7 m2.2 m4.6 m2.4 m2.6 m3.5 m4 m2.1 m2.1 m716 k
    show all
    USDY, 2018

    Financial Leverage

    		4.7 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Human Longevity
    Health - Private
    Agilent Technologies
    Health - Public
    Cepheid
    Health - Subsidiary
    Myriad Genetics
    Health - Public
    Compare competitors

    NanoString Technologies News and Updates

    May 08, 2018

    NanoString Technologies' (NSTG) CEO Brad Gray on Q1 2018 Results - Earnings Call Transcript

    Report incorrect company information
    Download PDF